Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.
| Revenue (TTM) | $9.59M |
| Gross Profit (TTM) | $9.03M |
| EBITDA | $-338.60M |
| Operating Margin | -2751.00% |
| Return on Equity | -137.40% |
| Return on Assets | -207.80% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $3.60 |
| Price-to-Book | 0.45 |
| Price-to-Sales (TTM) | 9.19 |
| EV/Revenue | 9.11 |
| EV/EBITDA | -0.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7290.00% |
| Shares Outstanding | $58.39M |
| Float | $40.33M |
| % Insiders | 22.26% |
| % Institutions | 28.12% |
Volatility is currently expanding